Aurinia Pharmaceuticals (NASDAQ:AUPH) Shares Up 3.3%

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSE:AUP)’s stock price rose 3.3% on Friday . The company traded as high as $7.15 and last traded at $7.14. 957,806 shares were traded during mid-day trading, a decline of 45% from the average daily volume of 1,728,562 shares. The stock had previously closed at $6.91.

Analyst Ratings Changes

Separately, HC Wainwright restated a “buy” rating and issued a $13.00 target price on shares of Aurinia Pharmaceuticals in a research note on Friday. One analyst has rated the stock with a hold rating and four have given a buy rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $10.00.

Aurinia Pharmaceuticals Stock Performance

The company has a market cap of $1.05 billion, a price-to-earnings ratio of -16.28 and a beta of 1.44. The firm’s 50-day moving average price is $5.88 and its 200 day moving average price is $5.51. The company has a debt-to-equity ratio of 0.18, a quick ratio of 4.82 and a current ratio of 5.33.

Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) last released its earnings results on Thursday, August 1st. The biotechnology company reported $0.01 earnings per share for the quarter, hitting the consensus estimate of $0.01. Aurinia Pharmaceuticals had a negative return on equity of 11.84% and a negative net margin of 24.31%. The firm had revenue of $57.10 million during the quarter, compared to analysts’ expectations of $54.25 million. During the same period in the prior year, the company earned ($0.08) earnings per share. The company’s quarterly revenue was up 37.6% on a year-over-year basis. On average, sell-side analysts anticipate that Aurinia Pharmaceuticals Inc. will post 0.13 EPS for the current year.

Insider Buying and Selling at Aurinia Pharmaceuticals

In other news, insider Scott Michael Habig sold 18,249 shares of the business’s stock in a transaction that occurred on Tuesday, August 6th. The stock was sold at an average price of $5.31, for a total value of $96,902.19. Following the sale, the insider now directly owns 456,338 shares of the company’s stock, valued at approximately $2,423,154.78. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. 4.30% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Aurinia Pharmaceuticals

Several hedge funds and other institutional investors have recently modified their holdings of AUPH. Cetera Advisors LLC lifted its stake in Aurinia Pharmaceuticals by 18.9% in the first quarter. Cetera Advisors LLC now owns 60,139 shares of the biotechnology company’s stock worth $301,000 after purchasing an additional 9,547 shares during the last quarter. Campbell & CO Investment Adviser LLC purchased a new stake in shares of Aurinia Pharmaceuticals in the 4th quarter valued at approximately $2,089,000. GSA Capital Partners LLP increased its position in shares of Aurinia Pharmaceuticals by 196.1% in the 1st quarter. GSA Capital Partners LLP now owns 349,204 shares of the biotechnology company’s stock valued at $1,750,000 after purchasing an additional 231,260 shares during the last quarter. Price T Rowe Associates Inc. MD lifted its holdings in shares of Aurinia Pharmaceuticals by 15.0% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 38,952 shares of the biotechnology company’s stock valued at $196,000 after purchasing an additional 5,079 shares during the last quarter. Finally, Vanguard Group Inc. raised its stake in shares of Aurinia Pharmaceuticals by 1.4% during the 1st quarter. Vanguard Group Inc. now owns 1,531,617 shares of the biotechnology company’s stock worth $7,673,000 after buying an additional 21,119 shares in the last quarter. 36.83% of the stock is currently owned by hedge funds and other institutional investors.

Aurinia Pharmaceuticals Company Profile

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.